Connected Drug Delivery Devices Market (2026 - 2033)

Connected Drug Delivery Devices Market Summary

The global connected drug delivery devices market size was valued at USD 9.1 billion in 2025 and is projected to grow from USD 11.2 billion in 2026 to USD 47.8 billion in 2033, at a CAGR of 23.0% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 30.0% in 2025. The increasing prevalence of chronic diseases such as asthma and diabetes, a strong shift in the healthcare industry toward remote patient monitoring and home-based care, and growing awareness of the benefits of automated tracking solutions for medication adherence and improved patient outcomes are key growth drivers for the connected drug delivery devices industry.

Partnerships and collaborations also contribute to the growth experienced by this market. For instance, in March 2025, Biocon and Civica, Inc. announced a strategic collaboration to expand access and enable the affordability of Insulin Aspart. This includes the Aspart drug substance supply from Biocon, enabling Civica to produce prefilled pens through Petersburg, Virginia-based manufacturing operations. Such developments are expected to facilitate the industry’s growth.

Market Dynamics

Analyst Perspective

A rapid pace of transition to digital therapeutics, growing adoption of technology-driven medical devices across various regions, increasing accessibility through e-commerce and online portals, and innovation are some of the key growth drivers for this market. Increasing awareness of benefits such as automated reminders, behavior-analysis-based insights, and support for medication adherence and remote monitoring contributes to growing adoption. Data security risks and rising cybercrimes may pose significant challenges for this market.

Product Insights

The standalone components and software segment dominated the connected drug delivery devices market in 2025. This is due to the increasing demand for connected sensors that transform traditional drug delivery devices into connected devices without interfering with their core functionality. The sensors can also be reused even if the device is disposable. Furthermore, the market has witnessed tremendous growth driven by technological innovation and the increasing connectivity of devices. In October 2025, Aptar.com., an advanced drug delivery device manufacturer, announced the FDA 510(k) Clearance for HeroTracker, which is an additional device attached to a pressurized Metered Dose Inhaler (pMDI).

The integrated devices segment is anticipated to grow at the fastest CAGR during the forecast period. The integrated devices can be employed for injection and Inhalational delivery systems, allowing patients to control their medication therapy even in remote places. The growing availability of integrated connected drug delivery devices is estimated to fuel segment growth. For instance, Elcam's FlexiQ eMU-P connected autoinjector is a self-administration tool for home usage suitable for the injection of high-viscosity drugs. It wirelessly transmits injection data to remote storage and also provides calendar settings and injection reminder alerts.

Route Of Administration Insights

The parenteral devices segment held the largest revenue share of the connected drug delivery devices industry in 2025, owing to the numerous advantages offered by smart & connected parenteral devices over conventional ones. The increasing prevalence of chronic diseases, including neurological disorders, diabetes, and cancer, is also anticipated to drive segment growth during the forecast period.

Inhalational devices are projected to grow at the fastest CAGR during the forecast period. This growth is attributed to the rising prevalence of respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disorders (COPD), and other respiratory diseases. R&D initiatives and product launches by key companies are also expected to contribute to segment growth in the coming years. 

Application Insights

The diabetes management segment dominated the connected drug delivery devices market, accounting for over 30.0% in 2025. This is owing to factors such as the rising prevalence of diabetes, technological advancements, and R&D in insulin delivery devices. Innovation-based software development, the inclusion of advanced technologies, and the increasing adoption of connected drug-delivery devices, such as smart insulin pens, are likely to strengthen the segment's growth potential.

The International Diabetes Federation estimated that about 589.0 million adults were living with diabetes in 2024. This number is projected to reach 853 million by 2050. The market is anticipated to experience a broad range of developments as connected drug delivery devices are constantly improving, which has the potential to transform the way diabetes is managed. The other applications segment is anticipated to grow the fastest CAGR during the forecast period. It comprises autoimmune diseases such as multiple sclerosis, migraine, and osteoporosis. 

Regional Insights

North America led the global connected drug delivery devices industry in 2025, accounting for a revenue share of over 30.0% in 2025. This is due to the region’s high per capita healthcare spending, rapid adoption of technology, presence of key players, and growing adoption of remote monitoring for medication adherence. Cognita Labs, LLC, for instance, is headquartered in the U.S. and has developed CapMedic (a Class II device) that works as an inhaler attachment for MDI. It measures the correctness, frequency, and timing of inhaler use and provides real-time audio-visual interactive guidance on correct usage.

Asia Pacific Connected Drug Delivery Devices Market Trends

The Asia Pacific connected drug delivery devices industry is anticipated to grow at the fastest CAGR over the forecast period. The growth of this market is primarily driven by growing awareness regarding technology-powered drug delivery devices, increasing adoption of remote patient monitoring, and semiconductor manufacturing capabilities of countries such as China and Taiwan. In March 2026, Zydus Lifesciences Limited announced the launch of Aerolife Mini, a portable and foldable spacer, featuring an exclusive licensing arrangement with AeroDel Technology Innovations Pvt. Ltd.

Key Connected Drug Delivery Devices Company Insights

The connected drug delivery devices market is highly fragmented in nature, with the presence of several large and small players. Large companies are publicly traded and have diverse portfolios with robust R&D, distribution, and sales capabilities. Medium- to small-sized companies focus on specific solutions that cater to customer needs in the market, e.g., sensor manufacturing and software for connected devices. Most market players implement strategic initiatives to grow their market presence and share. These include mergers and acquisitions, R&D, partnerships, regional expansion, and product launches.

Key Connected Drug Delivery Devices Companies

The following key companies have been profiled for this study of the connected drug delivery devices market.

• Teva Pharmaceutical Industries Ltd.

• Novo Nordisk A/S

• Phillips Medisize

• Medtronic

• Adherium

• Tandem Diabetes Care, Inc.

• Biocorp

• Ypsomed

• Propeller Health

• Aptar.com. 

Recent Developments

• In January 2025, Phillips Medisize announced that it had acquired Vectura Group Ltd., improving its inhalation drug delivery capabilities and adding strong know-how in metered dose inhalers, nasal inhalers, dry powder inhalers, and nebulizers, broadening Phillips Medisize's portfolio in pharmaceutical device design and manufacturing.

• In October 2024, Ypsomed announced the expansion of its manufacturing capabilities through the opening of a new production hall at its German site in Schwerin. This is expected to assist Ypsomed to address growing demand for high-quality medical technology products across various regions.

Connected Drug Delivery Devices Market Report Scope  

Global Connected Drug Delivery Devices Market Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global connected drug delivery devices market report based on product, route of administration, application, and region:

• Product Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • Standalone Components & Software

  • Integrated Devices

• Route of Administration Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • Parenteral

  • Inhalational

• Application Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • Asthma

  • COPD

  • Diabetes Management

  • Others

• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • South Arabia